Company Chairman and CEO to Present Clinical Status Report on QUILT Cancer Breakthrough 2020 Trials in Multiple Tumor Types and Data Update on the Company’s N-803 IL-15 Superagonist, which Recently Received Breakthrough Therapy Designation from the FDA 

CULVER CITY, Calif., January 7, 2020 – ImmunityBio, a privately held immunotherapy company focused on developing a T-cell memory cancer vaccine, today announced that Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:00 a.m. Pacific Time. The event will be held at the Westin St. Francis in San Francisco.

Dr. Soon-Shiong will present clinical updates and the registration strategy of the combination therapy of NantKwest’s off-the-shelf NK therapy with ImmunityBio’s N-803 molecule, as well as discuss the future relationship between the two companies’ immunotherapy platforms.

A live audio webcast of the conference presentation will be available on the ImmunityBio and NantKwest websites, immunitybio.com and NantKwest.com.  An archived replay will be available on the websites for approximately 30 days.

About ImmunityBio

ImmunityBio is a privately held immunotherapy company with a broad portfolio of biological molecules, including an albumin-linked chemotherapeutic, peptides, fusion proteins, cytokines, monoclonal antibodies, adenovirus, and yeast vaccine therapies.

ImmunityBio’s oncological goals are two-fold: To employ its broad portfolio of biological molecules to activate endogenous NK and CD8+ T cells, and to develop a T cell memory cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy.

The company’s platform of technologies has enabled it to achieve one of the most comprehensive, late-stage clinical pipelines, addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4 and CD8 killer T cells).  In 2020, ImmunityBio is planning to enroll patients in late-stage trials with molecules across multiple indications including triple negative breast cancer, lung cancer, head and neck cancer, Merkel cell carcinoma, and glioblastoma.

In the field of infectious disease, ImmunityBio’s goal is to develop vaccine therapies for the prevention and treatment of Influenza, Zika, Ebola, and HIV. For more information, please visit our website at https://www.immunitybio.com/


Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.   Forward-looking statements include statements concerning or implying that ImmunityBio will be successful in improving the treatment of cancer.  Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of ImmunityBio’s IL-15 based Cytokine therapy, N-803, and other therapeutics as part of the ImmunityBio portfolio.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.  We disclaim any obligation to update these statements except as may be required by law.

About NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally induced infectious diseases. Nantkwest is the leading producer of clinical dose forms of off-the-shelf Natural Killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally infected cells from the body. The safety of NantKwest’s optimized, activated NK cells, as well as their activity against a broad range of cancers, have been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit https://nantkwest.com.

haNK is a registered trademark of NantKwest, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

These and other risks regarding NantKwest’s business are described in detail in its Securities and Exchange Commission filings, including in NantKwest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Media & Investors:
Investors@ImmunityBio.com
Investors@NantKwest.com